Co‐mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome
Yanling Ren, Wei Lang, Chen Mei, Yingwan Luo, Li Ye, Lu Wang, Xinping Zhou, Gaixiang Xu, Liya Ma, Jie Jin, Hongyan Tong
Abstract
Abstract Single gene mutations in the RAS pathway are uncommon and of unknown significance in myelodysplastic syndrome (MDS) patients, RAS pathway‐related gene mutations ( RASway mut ) as a whole may be significant and require further elucidation. The clinical and molecular data of 370 MDS patients who were newly diagnosed between 1 November 2016 and 31 August 2020 in our hospital were collected and retrospectively reviewed. RASway mut were detected in 57 (15.41%) patients. Higher median percentage of marrow blasts (2% vs. 1%, P = 0.00), more co‐mutated genes (4, interquartile range [IQR]: 2–5. vs. 2, IQR:1–4, P = 0.00), more higher risk patients according to international prognostic scoring system‐revised (IPSS‐R) (80.70% vs. 59.11%, P = 0.002) as well as higher acute myeloid leukemia transformation rate (35.09% vs. 14.38%, P = 0.02) were observed in patients with RASway mut when compared to those with wild type RAS pathway‐related genes ( RASway wt ). The most frequent co‐mutated genes were ASXL1 (28.6%), TET2 (23.2%), U2AF1 , RUNX1 , TP53 (14.3%); DNMT3A (12.5%), among which ASXL1 mutation rate were significantly higher than those with RASway wt ( p < 0.05). RASway mut had no significant effect on response to disease‐modifying treatment in MDS patients. However, Overall survivals (OS) of RASway mut patients were significantly shorter than those with RASway wt (16.05 m. vs. 92.3 m, P = 0.00), especially in patients with marrow blasts less than 5% ( P = 0.002), normal karyotype ( P = 0.01) and lower risk ( P = 0.00). While multivariate prognostic analysis showed that RASway mut co‐mutated with TET2 was an independent poor prognostic factor for all MDS patients ( P = 0.00, hazrad ratio [HR] = 4.77 with 95% confidence interval [CI]: 2.4–9.51) and RASway mut patients ( P = 0.02, HR 2.76, 95% CI 1.21–6.29). In conclusion, RASway mut was associated with higher IPSS‐R risk, higher incidence of leukemic transformation thus shorter OS in MDS patients, it could be viewed as a whole to predict poor prognosis. Co‐mutation with TET2 may promote disease progression and was an independent poor prognostic factor in MDS patients.